Spanish private capital investment group, formerly GED Capital, investing through buyout, venture capital, healthcare and infrastructure strategies in Spain, Portugal and other European markets. It supports companies through acquisitions, operational development, international expansion and digitalisation, including adoption of AI. Its healthcare growth strategy, developed with Columbus Venture Partners, backs medicines, diagnostics, precision medicine, medical equipment, health software and scientific manufacturing services approaching or already in commercial operation. The group operates through regulated management companies including Buenavista Buyout, the registered manager of its healthcare and third buyout funds.
Founded
1996
Type
Venture capital
Funds2
Buenavista Buyout Innvierte III España, FCR—
Third Spanish buyout fund, launched9July2025 with a EUR250 million target. The manager confirmed a first close by20October2025 but did not disclose the amount in the reviewed sources. It targets8–10 platforms in healthcare, industry, services and food, with company growth, acquisitions, digitalisation and AI adoption. CDTI and Fond-ICO each subsequently committed up toEUR75 million; these LP commitments are not the total closed fund size. The legal manager is Buenavista Buyout, SGEIC, SA; CNMV fund registration538.
BV Healthcare Growth Innvierte I, FCR€100M
Healthcare growth fund with a EUR100 million first close announced9December2024. A EUR150 million hard cap and CDTI commitment of up toEUR58 million are distinct from closed fund size. The registered legal manager is Buenavista Buyout, S.A., SGEIC, formerly GED Iberian Private Equity, within the Buenavista group; the healthcare strategy is developed with Columbus Venture Partners. CNMV registry488 records registration30July2024. It targets10–12 mostly Spanish healthcare companies approaching commercialisation, including precision medicine, AI and health software, diagnostics and biopharmaceutical manufacturing.